Clinical evaluation of sulbactam plus ampicillin in the treatment of general pediatric infections

D. Bassetti, M. Solbiati, A. Ravelli, A. Martini, S. Viola, R. G. Burgio

Research output: Contribution to journalArticle

Abstract

Sixty pediatric patients (27 males and 33 females) between the ages of 7 months and 11.7 years (mean age = 4.3 yr) were treated with parenteral sulbactam plus ampicillin (1:2 ratio) for lower respiratory tract infections (29 cases), upper respiratory tract infections (4 cases), urinary tract infections (25 cases) or skin/soft tissue infections (2 cases). The infection was mild in 6 cases, moderate in 44 and severe in 10. The infection was acute in 57 patients, recurrent in 1 (cystitis) and was a flare-up of a chronic infection in 2 (pyelonephritis and cystitis). The children received an average dose of 48 mg/kg/d of sulbactam plus 96 mg/kg/d of ampicillin by the i.m. route (43 cases) or by i.v. drip (17 cases) in 3-4 divided doses. The length of treatment ranged between 3 and 10 d (mean duration = 6 d). At the end of therapy, clinical cure was achieved in 53 patients (88.3%), while 6 (10%) had a marked improvement. Only 1 patient, with a lower respiratory tract infection, did not respond to therapy. All 25 patients with urinary tract infection experienced bacteriological cure at the end of treatment. No side effects were reported. Mild and transient changes in laboratory parameters from baseline values were observed in 10 patients (eosinophilia, elevation of SGOT or SGPT) without clinical consequence. Sulbactam plus ampicillin was effective and safe in the treatment of bacterial infections in children and appears to be useful in the treatment of those infections in which β-lactamase-producing organisms are involved.

Original languageEnglish
Pages (from-to)41-44
Number of pages4
JournalAPMIS, Supplement
Volume97
Issue number5
Publication statusPublished - 1989

Fingerprint

Pediatrics
Infection
Respiratory Tract Infections
Cystitis
Urinary Tract Infections
Therapeutics
Sulbactam
Soft Tissue Infections
Pyelonephritis
Eosinophilia
Ampicillin
Aspartate Aminotransferases
Alanine Transaminase
Bacterial Infections
sultamicillin
Skin

ASJC Scopus subject areas

  • Immunology
  • Microbiology (medical)
  • Pathology and Forensic Medicine

Cite this

Clinical evaluation of sulbactam plus ampicillin in the treatment of general pediatric infections. / Bassetti, D.; Solbiati, M.; Ravelli, A.; Martini, A.; Viola, S.; Burgio, R. G.

In: APMIS, Supplement, Vol. 97, No. 5, 1989, p. 41-44.

Research output: Contribution to journalArticle

Bassetti, D. ; Solbiati, M. ; Ravelli, A. ; Martini, A. ; Viola, S. ; Burgio, R. G. / Clinical evaluation of sulbactam plus ampicillin in the treatment of general pediatric infections. In: APMIS, Supplement. 1989 ; Vol. 97, No. 5. pp. 41-44.
@article{895c15a69f2d4f8b9955edb9c5f4f2ae,
title = "Clinical evaluation of sulbactam plus ampicillin in the treatment of general pediatric infections",
abstract = "Sixty pediatric patients (27 males and 33 females) between the ages of 7 months and 11.7 years (mean age = 4.3 yr) were treated with parenteral sulbactam plus ampicillin (1:2 ratio) for lower respiratory tract infections (29 cases), upper respiratory tract infections (4 cases), urinary tract infections (25 cases) or skin/soft tissue infections (2 cases). The infection was mild in 6 cases, moderate in 44 and severe in 10. The infection was acute in 57 patients, recurrent in 1 (cystitis) and was a flare-up of a chronic infection in 2 (pyelonephritis and cystitis). The children received an average dose of 48 mg/kg/d of sulbactam plus 96 mg/kg/d of ampicillin by the i.m. route (43 cases) or by i.v. drip (17 cases) in 3-4 divided doses. The length of treatment ranged between 3 and 10 d (mean duration = 6 d). At the end of therapy, clinical cure was achieved in 53 patients (88.3{\%}), while 6 (10{\%}) had a marked improvement. Only 1 patient, with a lower respiratory tract infection, did not respond to therapy. All 25 patients with urinary tract infection experienced bacteriological cure at the end of treatment. No side effects were reported. Mild and transient changes in laboratory parameters from baseline values were observed in 10 patients (eosinophilia, elevation of SGOT or SGPT) without clinical consequence. Sulbactam plus ampicillin was effective and safe in the treatment of bacterial infections in children and appears to be useful in the treatment of those infections in which β-lactamase-producing organisms are involved.",
author = "D. Bassetti and M. Solbiati and A. Ravelli and A. Martini and S. Viola and Burgio, {R. G.}",
year = "1989",
language = "English",
volume = "97",
pages = "41--44",
journal = "APMIS. Supplementum",
issn = "0903-465X",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Clinical evaluation of sulbactam plus ampicillin in the treatment of general pediatric infections

AU - Bassetti, D.

AU - Solbiati, M.

AU - Ravelli, A.

AU - Martini, A.

AU - Viola, S.

AU - Burgio, R. G.

PY - 1989

Y1 - 1989

N2 - Sixty pediatric patients (27 males and 33 females) between the ages of 7 months and 11.7 years (mean age = 4.3 yr) were treated with parenteral sulbactam plus ampicillin (1:2 ratio) for lower respiratory tract infections (29 cases), upper respiratory tract infections (4 cases), urinary tract infections (25 cases) or skin/soft tissue infections (2 cases). The infection was mild in 6 cases, moderate in 44 and severe in 10. The infection was acute in 57 patients, recurrent in 1 (cystitis) and was a flare-up of a chronic infection in 2 (pyelonephritis and cystitis). The children received an average dose of 48 mg/kg/d of sulbactam plus 96 mg/kg/d of ampicillin by the i.m. route (43 cases) or by i.v. drip (17 cases) in 3-4 divided doses. The length of treatment ranged between 3 and 10 d (mean duration = 6 d). At the end of therapy, clinical cure was achieved in 53 patients (88.3%), while 6 (10%) had a marked improvement. Only 1 patient, with a lower respiratory tract infection, did not respond to therapy. All 25 patients with urinary tract infection experienced bacteriological cure at the end of treatment. No side effects were reported. Mild and transient changes in laboratory parameters from baseline values were observed in 10 patients (eosinophilia, elevation of SGOT or SGPT) without clinical consequence. Sulbactam plus ampicillin was effective and safe in the treatment of bacterial infections in children and appears to be useful in the treatment of those infections in which β-lactamase-producing organisms are involved.

AB - Sixty pediatric patients (27 males and 33 females) between the ages of 7 months and 11.7 years (mean age = 4.3 yr) were treated with parenteral sulbactam plus ampicillin (1:2 ratio) for lower respiratory tract infections (29 cases), upper respiratory tract infections (4 cases), urinary tract infections (25 cases) or skin/soft tissue infections (2 cases). The infection was mild in 6 cases, moderate in 44 and severe in 10. The infection was acute in 57 patients, recurrent in 1 (cystitis) and was a flare-up of a chronic infection in 2 (pyelonephritis and cystitis). The children received an average dose of 48 mg/kg/d of sulbactam plus 96 mg/kg/d of ampicillin by the i.m. route (43 cases) or by i.v. drip (17 cases) in 3-4 divided doses. The length of treatment ranged between 3 and 10 d (mean duration = 6 d). At the end of therapy, clinical cure was achieved in 53 patients (88.3%), while 6 (10%) had a marked improvement. Only 1 patient, with a lower respiratory tract infection, did not respond to therapy. All 25 patients with urinary tract infection experienced bacteriological cure at the end of treatment. No side effects were reported. Mild and transient changes in laboratory parameters from baseline values were observed in 10 patients (eosinophilia, elevation of SGOT or SGPT) without clinical consequence. Sulbactam plus ampicillin was effective and safe in the treatment of bacterial infections in children and appears to be useful in the treatment of those infections in which β-lactamase-producing organisms are involved.

UR - http://www.scopus.com/inward/record.url?scp=0024412458&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024412458&partnerID=8YFLogxK

M3 - Article

C2 - 2660870

AN - SCOPUS:0024412458

VL - 97

SP - 41

EP - 44

JO - APMIS. Supplementum

JF - APMIS. Supplementum

SN - 0903-465X

IS - 5

ER -